Paul Bröckelmann
@broeckelmann.bsky.social
Physician Scientist in Cologne, interested in Hemato-Oncology, Lymphoma & Immunotherapy. Views are mine & no advise, repost/like no endorsement. COI: http://bit.ly/34MaLOt
Great to see another study w high efficacy of low-dose nivolumab (40mg Q2W; plus lenalidomide) in relapsed Hodgkin lymphoma: 90% ORR (60% CR, 30% PR), promising PFS & saturated PD1 receptor occupancy. Do we really need 240mg Q2W? www.sciencedirect.com/science/arti... @bloodjournals.hematology.org
November 13, 2025 at 8:36 PM
Great to see another study w high efficacy of low-dose nivolumab (40mg Q2W; plus lenalidomide) in relapsed Hodgkin lymphoma: 90% ORR (60% CR, 30% PR), promising PFS & saturated PD1 receptor occupancy. Do we really need 240mg Q2W? www.sciencedirect.com/science/arti... @bloodjournals.hematology.org
Very happy to share our new Blood Spotlight Review on patterns of immune-related toxicities with anti-PD1 first-line treatment of Hodgkin lymphoma and remaining uncertainties @bloodjournals.hematology.org: doi.org/10.1182/bloo... Congrats to GHSG Physician Christian Jaworek for spearheading this!
November 4, 2025 at 10:04 AM
Very happy to share our new Blood Spotlight Review on patterns of immune-related toxicities with anti-PD1 first-line treatment of Hodgkin lymphoma and remaining uncertainties @bloodjournals.hematology.org: doi.org/10.1182/bloo... Congrats to GHSG Physician Christian Jaworek for spearheading this!
Excited to share our preprint on the new HaJo cell line and robust systemic PDX in vivo model includin comprehensive characterization to enable further research in rare non-MCL B-cell lymphoma with CCND1 re-arrangement: www.biorxiv.org/content/10.1...
@mpiage.bsky.social @uniklinikkoeln.bsky.social
@mpiage.bsky.social @uniklinikkoeln.bsky.social
September 3, 2025 at 8:35 AM
Excited to share our preprint on the new HaJo cell line and robust systemic PDX in vivo model includin comprehensive characterization to enable further research in rare non-MCL B-cell lymphoma with CCND1 re-arrangement: www.biorxiv.org/content/10.1...
@mpiage.bsky.social @uniklinikkoeln.bsky.social
@mpiage.bsky.social @uniklinikkoeln.bsky.social
Honoured to have contributed a @bloodjournals.hematology.org Commentary (doi.org/10.1182/bloo...) on a recent study by @drmiguelperales.bsky.social @mskcancercenter.bsky.social highlighting improved outcomes with alloSCT in r/r cHL after prior ICI exposure (doi.org/10.1182/bloo...)
August 26, 2025 at 1:11 PM
Honoured to have contributed a @bloodjournals.hematology.org Commentary (doi.org/10.1182/bloo...) on a recent study by @drmiguelperales.bsky.social @mskcancercenter.bsky.social highlighting improved outcomes with alloSCT in r/r cHL after prior ICI exposure (doi.org/10.1182/bloo...)
Longitudinal measurement of serum TARC shows rapid early cHL response to first-line nivolumab monotherapy and N-AVD. Potential to guide individualized immunotherapy? Great collaboration with W. Plattel @rug.nl now published @hemasphere-journal.bsky.social: onlinelibrary.wiley.com/doi/epdf/10....
August 26, 2025 at 1:03 PM
Longitudinal measurement of serum TARC shows rapid early cHL response to first-line nivolumab monotherapy and N-AVD. Potential to guide individualized immunotherapy? Great collaboration with W. Plattel @rug.nl now published @hemasphere-journal.bsky.social: onlinelibrary.wiley.com/doi/epdf/10....
Great to see the results of a joint NLG x GHSG academic phase 2 trial @hemasphere-journal.bsky.social: First-line treatment with B-CAP is feasible and effective in older patients with advanced-stage cHL, with improvement of most patient-reported HRQoL domains onlinelibrary.wiley.com/doi/10.1002/...
August 25, 2025 at 7:54 PM
Great to see the results of a joint NLG x GHSG academic phase 2 trial @hemasphere-journal.bsky.social: First-line treatment with B-CAP is feasible and effective in older patients with advanced-stage cHL, with improvement of most patient-reported HRQoL domains onlinelibrary.wiley.com/doi/10.1002/...
The 2-year PFS (91.5%) and OS after 4-6x BrECADD are unprecedented and indicate the high curative potential of an intensified approach in this historically challenging subgroup. Best outcomes in 60-65 years, more dose level reductions in frail patients.
July 24, 2025 at 3:31 PM
The 2-year PFS (91.5%) and OS after 4-6x BrECADD are unprecedented and indicate the high curative potential of an intensified approach in this historically challenging subgroup. Best outcomes in 60-65 years, more dose level reductions in frail patients.
Individual patient trajectories indicate short and anthracycline-sparing treatment with 4x BrECADD in 2/3 of the patients (PET2-negative), while also PET2-positive patients are able to achieve PET-negativity at EOT and favorable long-term outcomes. Improved QoL and Fatigue after 4-6x BrECADD.
July 24, 2025 at 3:31 PM
Individual patient trajectories indicate short and anthracycline-sparing treatment with 4x BrECADD in 2/3 of the patients (PET2-negative), while also PET2-positive patients are able to achieve PET-negativity at EOT and favorable long-term outcomes. Improved QoL and Fatigue after 4-6x BrECADD.
Toxicity was mainly hematologic with associated febrile neutropenia (55%), infections, mucositis and gastrointestinal disorders. PNP of mostly grade 1 occurred in 40% No treatment-related mortality was reported. Most symptoms remained stable on and improved after BrECADD (as did functioning scales)
July 24, 2025 at 3:31 PM
Toxicity was mainly hematologic with associated febrile neutropenia (55%), infections, mucositis and gastrointestinal disorders. PNP of mostly grade 1 occurred in 40% No treatment-related mortality was reported. Most symptoms remained stable on and improved after BrECADD (as did functioning scales)
The HD21 Older Cohort was an international, multicenter single-arm phase 2 add-on to the randomized HD21 trial and recruited N=83 evaluable patients. 89% of patients received target no. of 4 or 6 cycles, with frequent use of per-protocol defined dose reductions.
July 24, 2025 at 3:31 PM
The HD21 Older Cohort was an international, multicenter single-arm phase 2 add-on to the randomized HD21 trial and recruited N=83 evaluable patients. 89% of patients received target no. of 4 or 6 cycles, with frequent use of per-protocol defined dose reductions.
Our analysis of the HD21 Older Cohort is now published in the JCO @ascocancer.bsky.social doi.org/10.1200/JCO-... @ferdinandusj.bsky.social 🎉 Key take away: PET-guided 4-6x BrECADD is feasible and highly effective in older AS-cHL patients 60-75 years of age, thereby expanding treatment options 🧵👀👇
July 24, 2025 at 3:31 PM
Our analysis of the HD21 Older Cohort is now published in the JCO @ascocancer.bsky.social doi.org/10.1200/JCO-... @ferdinandusj.bsky.social 🎉 Key take away: PET-guided 4-6x BrECADD is feasible and highly effective in older AS-cHL patients 60-75 years of age, thereby expanding treatment options 🧵👀👇
Really good to see improved gonadal function recovery and child birth rates after 4-6x BrECADD vs eBEACOPP in advanced-stage HL. Results now published are further supporting BrECADD as preferred treatment: @thelancetoncol.bsky.social doi.org/10.1016/S147... Congrats to the international HD21 team.
July 11, 2025 at 8:51 AM
Really good to see improved gonadal function recovery and child birth rates after 4-6x BrECADD vs eBEACOPP in advanced-stage HL. Results now published are further supporting BrECADD as preferred treatment: @thelancetoncol.bsky.social doi.org/10.1016/S147... Congrats to the international HD21 team.
3-year follow-up of TRANSFORM @ascocancer.bsky.social confirms significantly improved PFS with lisocel compared to SOC as second-line treatment for r/r LBCL (51% vs 26%): ascopubs.org/doi/10.1200/... PRO indicate improved HRQoL incl. Fatigue on treatment with lisocel, but similar long-term outcomes.
July 8, 2025 at 9:34 AM
3-year follow-up of TRANSFORM @ascocancer.bsky.social confirms significantly improved PFS with lisocel compared to SOC as second-line treatment for r/r LBCL (51% vs 26%): ascopubs.org/doi/10.1200/... PRO indicate improved HRQoL incl. Fatigue on treatment with lisocel, but similar long-term outcomes.
Congrats to Daniel Bachurski @uniklinikkoeln.bsky.social on a very nice, comprehensive review @febsletters.bsky.social on biological and technical approaches to study extracellular vesicles in B-cell malignancies. Rapid progress & unprecedented insights: febs.onlinelibrary.wiley.com/doi/epdf/10....
July 6, 2025 at 3:23 PM
Congrats to Daniel Bachurski @uniklinikkoeln.bsky.social on a very nice, comprehensive review @febsletters.bsky.social on biological and technical approaches to study extracellular vesicles in B-cell malignancies. Rapid progress & unprecedented insights: febs.onlinelibrary.wiley.com/doi/epdf/10....
Impressive, thought provoking preprint (arxiv.org/pdf/2506.22405) by a Microsoft AI team: Much higher diagnostic accuracy (80% vs 20%) and 20% lower costs with iteratively thinking "MAI Diagnostic Orchestrator" vs Generalist Physicians. Elegant study building on >300 @nejm.org case reports.
June 30, 2025 at 3:10 PM
Impressive, thought provoking preprint (arxiv.org/pdf/2506.22405) by a Microsoft AI team: Much higher diagnostic accuracy (80% vs 20%) and 20% lower costs with iteratively thinking "MAI Diagnostic Orchestrator" vs Generalist Physicians. Elegant study building on >300 @nejm.org case reports.
It’s indeed exciting that we are starting to see clinical impact of biological patterns. The immune inflamed microenvironment in EBV+ cHL (e.g. doi.org/10.1158/1078...) seems prone to ICI. Hereto, we will present data on ctDNA HL subtypes w exceptional benefit of nivo monotherapy at #18ICML on Fri
June 18, 2025 at 5:14 PM
It’s indeed exciting that we are starting to see clinical impact of biological patterns. The immune inflamed microenvironment in EBV+ cHL (e.g. doi.org/10.1158/1078...) seems prone to ICI. Hereto, we will present data on ctDNA HL subtypes w exceptional benefit of nivo monotherapy at #18ICML on Fri
6x Nivo-AVD with PFS & OS benefit and better tolerability vs 6x BV-AVD in AS-HL pts ≥60 years in the randomised S1826 trial. Efficacy driven by EBV status? PRO-CTCAE confirming better tolerability & revealing discrepancy to physician reporting @ascocancer.bsky.social ascopubs.org/doi/10.1200/...
June 17, 2025 at 8:56 AM
6x Nivo-AVD with PFS & OS benefit and better tolerability vs 6x BV-AVD in AS-HL pts ≥60 years in the randomised S1826 trial. Efficacy driven by EBV status? PRO-CTCAE confirming better tolerability & revealing discrepancy to physician reporting @ascocancer.bsky.social ascopubs.org/doi/10.1200/...
#18ICML does not only feature exciting new data across lymphomas presented at one of the most beautiful conferences, but a great Educational: onlinelibrary.wiley.com/toc/10991069... Recommend the evaluation of T-cell redirecting strategies by Gloria Iacoboni onlinelibrary.wiley.com/doi/full/10....
June 16, 2025 at 3:51 PM
#18ICML does not only feature exciting new data across lymphomas presented at one of the most beautiful conferences, but a great Educational: onlinelibrary.wiley.com/toc/10991069... Recommend the evaluation of T-cell redirecting strategies by Gloria Iacoboni onlinelibrary.wiley.com/doi/full/10....
Getting ready for the Hematology in Focus Session on Hodgkin Lymphoma at #EHA2025 ☕️🥐🇮🇹 Join us in Gold Hall at 8am to discuss the exciting developments in the field.
June 15, 2025 at 5:39 AM
Getting ready for the Hematology in Focus Session on Hodgkin Lymphoma at #EHA2025 ☕️🥐🇮🇹 Join us in Gold Hall at 8am to discuss the exciting developments in the field.
Heartfelt congrats to David, Roland and the whole @uniklinikkoeln.bsky.social lymphoma team! Great to see our exciting study on targeting CSF1R+ myeloid-monocytic cells to overcome CAR-T cell resistance now published online in Cancer Cell @cp-cancercell.bsky.social: doi.org/10.1016/j.cc... 🎉
June 13, 2025 at 8:14 AM
Heartfelt congrats to David, Roland and the whole @uniklinikkoeln.bsky.social lymphoma team! Great to see our exciting study on targeting CSF1R+ myeloid-monocytic cells to overcome CAR-T cell resistance now published online in Cancer Cell @cp-cancercell.bsky.social: doi.org/10.1016/j.cc... 🎉
Lastly, we highlight challenges, unmet needs, and future perspectives for tolerability assessment of novel therapies. Looking forward to chair the joint EHA-EMA session at #EHA2025, where we will hear and discuss perspectives from multiple stakeholders: tinyurl.com/4snaps6c
May 30, 2025 at 10:30 AM
Lastly, we highlight challenges, unmet needs, and future perspectives for tolerability assessment of novel therapies. Looking forward to chair the joint EHA-EMA session at #EHA2025, where we will hear and discuss perspectives from multiple stakeholders: tinyurl.com/4snaps6c
While there is often excitement with novel therapies, there are uncertainties with regard to their toxicity profile, especially if moving to earlier lines of treatment or curative intent. We argue, to critically revisiting dose and duration of treatment to avoid cumulative + financial toxicities.
May 30, 2025 at 10:30 AM
While there is often excitement with novel therapies, there are uncertainties with regard to their toxicity profile, especially if moving to earlier lines of treatment or curative intent. We argue, to critically revisiting dose and duration of treatment to avoid cumulative + financial toxicities.
First, we highlight the increasing use of targeted therapeutics and associated short, mid- and long-term safety profile of these approaches. Building on experiences in the CAR-T cell field, we next outline strategies for multi-stakeholder tolerability assessment during the drug development process.
May 30, 2025 at 10:30 AM
First, we highlight the increasing use of targeted therapeutics and associated short, mid- and long-term safety profile of these approaches. Building on experiences in the CAR-T cell field, we next outline strategies for multi-stakeholder tolerability assessment during the drug development process.
For the third (open access) paper, I was humbled to coordinate an international author panel to comprehensively summarize challenges, lessons learned and outline future strategies for tolerability assessment with novel, targeted therapeutic approaches: doi.org/10.1016/S235...
May 30, 2025 at 10:30 AM
For the third (open access) paper, I was humbled to coordinate an international author panel to comprehensively summarize challenges, lessons learned and outline future strategies for tolerability assessment with novel, targeted therapeutic approaches: doi.org/10.1016/S235...
In the second paper, Vishal Bhatnagar (FDA) and co-authors explore use of patient-reported data / outcomes (PROs) to inform tolerability of treatment approaches in haematologic malignancies: doi.org/10.1016/S235...
May 30, 2025 at 10:30 AM
In the second paper, Vishal Bhatnagar (FDA) and co-authors explore use of patient-reported data / outcomes (PROs) to inform tolerability of treatment approaches in haematologic malignancies: doi.org/10.1016/S235...